EuroBiotech Report—AstraZeneca's lupus filing, Roche SMA data, Kiadis cuts, Genfit and Merck

Map of Europe
(Pixabay)

Welcome to the latest edition of our weekly EuroBiotech Report. We start this week with upbeat late-phase updates from Big Pharma companies. AstraZeneca is lining up a 2020 filing for anifrolumab in lupus on the strength of data it thinks show the drug works, despite one of the phase 3 trials missing its primary endpoint. Meanwhile, Roche revealed a phase 3 trial of its challenger for the spinal muscular atrophy market has met its primary endpoint, setting the stage for a showdown with Biogen and Novartis. Elsewhere, Kiadis Pharma dumped its lead drug and laid off half its staff. Genfit CEO Pascal Prigent set out his vision for a nonalcoholic steatohepatitis diagnostic. Merck moved to cut 100 R&D jobs at a French site. And more. — Nick Taylor
 
1. AstraZeneca plans 2020 filing for anifrolumab in lupus

AstraZeneca is planning to file for approval of anifrolumab in systemic lupus erythematosus in the second half of next year. The Big Pharma is confident data generated across mid- and late-phase trials show the anti-IFNAR1 antibody works despite a pivotal study missing its primary goal.
 
2. Roche's challenger for SMA market hits goal in phase 3

A phase 3 trial of Roche’s risdiplam in patients with type 2 or 3 spinal muscular atrophy (SMA) has met its primary endpoint. The results tee Roche up to file for approval to compete with Biogen and Novartis in the increasingly crowded SMA market.
 
3. Kiadis dumps phase 3 drug, halves head count in pivot to NK cells

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

Kiadis has dropped its lead program midway through a phase 3 trial. The action will see Kiadis lay off half of its staff and switch its attention to earlier-stage natural killer cell therapies against solid tumors and hematological cancers.
 
4. Prigent on better NASH tests for R&D and the doctor's office

What the nonalcoholic steatohepatitis (NASH) field needs, says Genfit CEO Pascal Prigent, is something like Hb1Ac for diabetes: a test that’s easy to do and that’s “commonly regarded as the right way to monitor the disease that everybody can use.” To that end, Genfit is working on a blood test that could become the first diagnostic approved specifically for NASH.
 
5. Merck to slash more than 100 R&D jobs from French site

While Merck announced it was spending a few hundred million on an early-stage biotech this week, we have learned it is also shuttering an R&D site in Riom in the heart of France.
 
And more articles of note>>    

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.